• Explore /
  • Poster
  • / Commercial health plan spending on oncology drugs approved via the accelerated approval pathway and later withdrawn from the market.

Commercial health plan spending on oncology drugs approved via the accelerated approval pathway and later withdrawn from the market.

Abstract Poster

Authors

null

Tejas Patel

UnitedHealthcare, Minnetonka, MN

Tejas Patel , Eamonn Curran , Sarah S Hellems

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Quality Care/Health Services Research

Track

Care Delivery and Quality Care

Sub Track

Real-World Data/Outcomes

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 11134)

DOI

10.1200/JCO.2024.42.16_suppl.11134

Abstract #

11134

Poster Bd #

329

Abstract Disclosures

Similar Posters

First Author: Amit Sanyal

First Author: Courtney Williams

First Author: Devalingam Mahalingam

First Author: Michael J. Overman